KM Research Hub

LITERATURE

符合新入排标准的活动候选

仅显示 v3 复核后仍在自动处理队列中的候选论文。 共 1883 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Novel approach of prophylactic radiation to reduce toxicities comparing 2-step40 with 56-Gy simultaneous integrated boost intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the head and neck, an intergroup phase III trial (JCOG1912, NEW BRIDGE).BMC CancerPMID 37932681PMC106267032023-Nov-060.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer.Endocr Relat CancerPMID 37671811PMC113040322023-Nov-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A Multicenter Survey on Eligibility for a Randomized Phase III Trial of Adjuvant Chemotherapy for Resected Biliary Tract Cancer (JCOG1202, ASCOT).Ann Surg OncolPMID 37450093无 PMCID2023-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study.Gastric CancerPMID 37548812PMC106404802023-Nov0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.Ann OncolPMID 37678672无 PMCID2023-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial.Lancet Gastroenterol HepatolPMID 37734399PMC105675792023-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab.Curr Med Res OpinPMID 37752878无 PMCID2023-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
The safety and efficacy of total mesorectal excision (TME) surgery following dose-escalation: Surgical outcomes from the organ preservation in early rectal adenocarcinoma (OPERA) trial, a European multicentre phase 3 randomised trial (NCT02505750).Colorectal DisPMID 37837240无 PMCID2023-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.Nat MedPMID 37845511PMC106670902023-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial.Br J CancerPMID 37864049PMC106672122023-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.Lancet OncolPMID 37875143无 PMCID2023-Nov1.00命中用户提供的消化道肿瘤阳性参考集。待处理
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial.Lancet HaematolPMID 37914482无 PMCID2023-Nov0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.LancetPMID 37633306无 PMCID2023-Oct-210.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.J Clin OncolPMID 37364223PMC106024972023-Oct-200.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.J Clin OncolPMID 37643382PMC106025392023-Oct-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.J Clin OncolPMID 37651676PMC106025072023-Oct-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.N Engl J MedPMID 37851874无 PMCID2023-Oct-190.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.BMC CancerPMID 37838670PMC105763212023-Oct-140.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial.J Clin OncolPMID 37506329PMC105643082023-Oct-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.LancetPMID 37708904PMC116641542023-Oct-071.00命中用户提供的消化道肿瘤阳性参考集。待处理
Short-term outcomes of Early versus conventional adjuvant chemotherapy in stage III colon cancer: randomized clinical trial.BJS OpenPMID 37439066PMC103388992023-Oct-030.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Comparison of Changes in Pulmonary Function After Stereotactic Body Radiation Therapy Versus Conventional 3-Dimensional Conformal Radiation Therapy for Stage I and IIA Non-Small Cell Lung Cancer: An Analysis of the TROG 09.02 (CHISEL) Phase 3 Trial.Int J Radiat Oncol Biol PhysPMID 37087060无 PMCID2023-Oct-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer.JAMA SurgPMID 37466971PMC103573582023-Oct-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10).Cancer Res TreatPMID 37232070PMC106455182023-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study.Lancet Respir MedPMID 37244266无 PMCID2023-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.Clin Genitourin CancerPMID 37263910无 PMCID2023-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients' With HER2-Positive Metastatic Breast Cancer.Clin Breast CancerPMID 37423801无 PMCID2023-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.Ann OncolPMID 37467930无 PMCID2023-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.LeukemiaPMID 37604981PMC105391672023-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A randomized phase III study of docetaxel alone versus docetaxel plus S-1 in patients with previously treated non-small cell lung cancer: JMTO LC09-01.Thorac CancerPMID 37609677PMC105699022023-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study.Lancet Diabetes EndocrinolPMID 37619579PMC105227782023-Oct0.90The record is a phase 3 randomized trial of adjuvant mitotane versus surveillance in adrenocortical carcinoma with a primary time-to-event endpoint (RFS) and secondary OS, reporting hazard ratios. It meets all eligibility criteria for an original formal result.待处理
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.Gynecol OncolPMID 37625235PMC109864252023-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.Lancet OncolPMID 37708912无 PMCID2023-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.Lancet OncolPMID 37714168无 PMCID2023-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.Lancet HaematolPMID 37793771无 PMCID2023-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.Lancet HaematolPMID 37793772无 PMCID2023-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.J Immunother CancerPMID 37903590PMC106191232023-Oct0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.LancetPMID 37499670无 PMCID2023-Sep-300.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma.Blood AdvPMID 37379264PMC104719382023-Sep-120.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.J Clin OncolPMID 37379502无 PMCID2023-Sep-100.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia.Sci RepPMID 37684299PMC104916262023-Sep-080.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.Int J Gynecol CancerPMID 37666539无 PMCID2023-Sep-040.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse.J Clin OncolPMID 37257143PMC108523662023-Sep-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.Clin Cancer ResPMID 37379430无 PMCID2023-Sep-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.JAMA OncolPMID 37440217PMC103465052023-Sep-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Lead Time to Recurrence After Posttreatment Plasma and Saliva HPV DNA Testing in Patients With Low-Risk HPV Oropharynx Cancer.JAMA Otolaryngol Head Neck SurgPMID 37498566PMC103753882023-Sep-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer.J Gastrointest CancerPMID 37037952PMC106131412023-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework.Clin Pharmacol TherPMID 37212707无 PMCID2023-Sep0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.J Thorac OncolPMID 37236398无 PMCID2023-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506).Breast Cancer Res TreatPMID 37365483PMC103618832023-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理